The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.

MD, PhD

Jean-David Bouaziz +2 more

Learning objectives

Highlight the cumulative impact of type 2 inflammation on the lives of patients with AD, beyond signs and symptoms
Explore the concepts of disease modification and early intervention and how biomarkers might help inform management of AD
Investigate the potential of targeting type 2 inflammation to achieve disease modification, including impact on atopic and non-atopic comorbidities

About these experts

Dermatology

MD, PhD

Jean-David Bouaziz

Professor of Dermatology, Université Paris Cité Head of the Department of Dermatology | Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris

Dermatology

MD, MS

Amy Paller

Walter J. Hamlin Professor and Chair of Dermatology; Professor of Pediatrics at Northwestern University, Evanston, Illinois, US

Dermatology

Alan Irvine

Professor of Dermatology, Trinity College, Dublin, Ireland

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region